PATENT CLAIM ANALYSIS

Application Number: 16060299
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-12
Patent Classification: ["514", "314000"]

Abstract:
The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of Cezanne 1 and ubiquitin C-terminal hydrolase 30 or Ubiquitin Specific Peptidase 30 (USP30). The invention further relates to the use of DUB inhibitors in the treatment of cancer. Compounds of the invention include compounds having the formula (I): pharmaceutically acceptable salt thereof, wherein R 1a , R 1b , R 1c , R 1d , R 1e , R 1f  and A are as defined herein.

Claim (Index 16):
A pharmaceutical composition, comprising a compound according to  claim 1 , or a pharmaceutically acceptable salt thereof together, with one or more pharmaceutically acceptable excipients.

Metadata:
- Claim Count in Document: 47.0
- Percentile: 94.0
- Lexical Diversity: 1.65625
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['16070936', '15894025', '15513125', '16078518', '15738900']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8157059234396485
- 35 USC 102 Novelty (BERT): 0.5805568028406921
- Combined Prediction Score: 0.792191011379753
- Mean Citation Score: 442.800168
- Max Citation Score: 484.3908
- Similarity Product: 442.4000544965028

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test